Speciating volatile organic compounds in indoor air: using GC to interpret real-time PTR-MS signals.

Proton transfer reaction mass spectrometry (PTR-MS) is often employed to characterize gas-phase compounds in both indoor and outdoor environments. PTR-MS measurements are usually made without upstream chromatographic separation, so it can be challenging to differentiate between an ion of interest, its isomers, and fragmentation products from other species all detected at the same mass-to-charge ratio. These isomeric contributions and fragmentation interferences can confound the determination of accurate compound mixing ratios, the assignment of accurate chemical properties, and corresponding analyses of chemical fate.

Update from 2010 (standard operating procedure): protocol for the 2024 British Society of Gastroenterology Guidelines on colorectal surveillance in inflammatory bowel disease.

Introduction: The evolving landscape of inflammatory bowel disease (IBD) necessitates refining colonoscopic surveillance guidelines. This study outlines methodology adopted by the British Society of Gastroenterology (BSG) Guideline Development Group (GDG) for updating IBD colorectal surveillance guidelines.

Methods And Analysis: The 'Grading of Recommendations, Assessment, Development and Evaluation' (GRADE) approach, as outlined in the GRADE handbook, was employed.

Dynamics of residential indoor gas- and particle-phase water-soluble organic carbon: measurements during the CASA experiment.

Previous time-integrated (2 h to 4 h) measurements show that total gas-phase water-soluble organic carbon (WSOC) is 10 to 20 times higher inside homes compared to outside. However, concentration dynamics of WSOC and total particle phase WSOC (WSOC)-are not well understood. During the Chemical Assessment of Surfaces and Air (CASA) experiment, we measured concentration dynamics of WSOC and WSOC inside a residential test facility in the house background and during scripted activities.

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Purpose: Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate with an SN-38 payload, approved for patients with locally advanced (LA) or metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). Here, we report results from Cohort 2 of TROPHY-U-01 trial, evaluating the efficacy and safety of SG in patients with mUC.

Methods: TROPHY-U-01 (ClinicalTrials.